| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 100,20 | 100,34 | 21:19 | |
| 100,06 | 100,44 | 21:18 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 115,00 | 67 | |||
| 110,00 | 260 | |||
| 100,56 | 78 | |||
| 100,44 | 150 | |||
| 100,42 | 891 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/6mk.htm [/URL] | ||||
| 966 | 100,26 | |||
| 78 | 100,14 | |||
| 15 | 98,47 | |||
| 5 | 98,45 | |||
| 5 | 98,43 | |||
| 75 | 79,50 | |||
| 1.094 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.238 | 0,646 | 1.446 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:27:21 | 99,55 | 20 |
| 17:10:23 | 99,72 | 98 |
| 17:09:43 | 99,63 | 5 |
| 16:37:05 | 99,50 | 100 |
| 16:37:05 | 99,51 | 19 |
| 16:31:41 | 100,00 | 1 |
| 14:40:05 | 101,44 | 28 |
| 13:00:30 | 102,20 | 25 |
| 13:00:30 | 102,08 | 48 |
| 13:00:30 | 102,06 | 75 |
| 13:00:30 | 102,04 | 102 |
| 11:15:15 | 101,86 | 49 |
| 11:04:59 | 101,90 | 27 |
| 10:32:43 | 101,86 | 32 |
| 10:32:34 | 101,86 | 25 |
| 10:19:03 | 101,50 | 22 |
| 10:01:43 | 101,78 | 50 |
| 09:27:24 | 101,80 | 20 |
| 09:26:33 | 101,62 | 34 |
| Tagesumsatz Xetra | -2,45 -2,40 % | 1.520 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17:09 | Merck & Co. (MRK): Die Bullen lauern an der 20-Tagelinie! | 341 | ratgeberGELD.at | Konsolidierung auf hohem Niveau! Rückblick Die Aktie von Merck befindet sich in einer Korrekturphase innerhalb eines starken Aufwärtstrends. Der Markt "atmet durch", nachdem die Kurse schnell gestiegen... ► Artikel lesen | |
| 14:10 | Will Keytruda Continue to Aid Merck's Top Line in Q1 Earnings? | 4 | Zacks | ||
| MERCK & CO Aktie jetzt für 0€ handeln | |||||
| 13:05 | This Merck (MRK) Stock Bullish Diagonal Trade Targets a Price of $130 by June 18 | 3 | Barchart.com | ||
| Di | MRK, Daiichi's BLA for ADC Drug Gets FDA Priority Tag in Lung Cancer | 3 | Zacks | ||
| Di | MSD, Daiichi Sankyo's ifinatamab deruxtecan receives FDA priority | 9 | Pharmaceutical Technology |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 09:06 | JEFFERIES stuft NOVO NORDISK auf 'Hold' | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Novo Nordisk auf "Hold" mit einem Kursziel von 270 dänischen Kronen belassen. Die Nachfragen der US-Zulassungsbehörde FDA... ► Artikel lesen | |
| 13:42 | Tilray Brands, Inc.: Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership | GlobeNewswire (Europe) | NEW YORK and LEAMINGTON, Ontario, April 15, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc.?("Tilray", "our", "we" or the "Company") (NASDAQ: TLRY; TSX: TLRY), a global lifestyle and consumer packaged... ► Artikel lesen | |
| 14:10 | Teva Pharmaceutical Industries Ltd: Teva Launches Home Ground Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners | GlobeNewswire (Europe) | For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground Schizophrenia Community is a centralized destination that... ► Artikel lesen | |
| 13:06 | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications | GlobeNewswire (Europe) | Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior executive, Office Secretary of Defense) to serve... ► Artikel lesen | |
| 15:04 | Wayfinder Biosciences, Inc.: Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase | PR Newswire | SEATTLE, April 15, 2026 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company using small molecules to target undruggable proteins at the RNA level, today... ► Artikel lesen |